Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the contraceptive efficacy and safety of an oral contraceptive containing a combination of LNG 100mcg/EE 20mcg compared to LNG 150mcg/EE 30 mcg.


Clinical Trial Description

n/a


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02021097
Study type Interventional
Source Regenex Pharmaceutical, China
Contact Chengliang Xiong, Dr
Email clxiong951@sina.cn
Status Recruiting
Phase Phase 3
Start date February 2012
Completion date February 2016

See also
  Status Clinical Trial Phase
Completed NCT01388491 - A Multinational Study to Evaluate the Effects of a 28-Day Oral Contraceptive on Hemostatic Parameters in Healthy Women Phase 2
Completed NCT01252186 - A Multicenter Study to Evaluate the Effects of a 91-Day Extended Cycle Oral Contraceptive on Hemostatic Parameters in Healthy Women Phase 2
Recruiting NCT02398903 - Evaluation of Hormonal Contraceptive Treatments in Obese Women
Completed NCT00302666 - Bleeding Pattern Study Phase 3
Completed NCT00739622 - TMC278-TiDP6-C136: Effect of TMC278 on Ethinylestradiol and Norethindrone in Healthy Women. Phase 1
Completed NCT01291004 - A Study to Evaluate Ovarian Follicular Activity and Hormone Levels for DR-102 Compared to Two 28-Day Oral Contraceptives Phase 1
Recruiting NCT01318005 - Oral Contraceptive (OC) Estrogen Dose and Breast Proliferation N/A
Completed NCT00778609 - Effect of a New Oral Contraceptive Pill on Hormone Related Symptoms Such as Pelvic Pain and Headache Phase 3
Completed NCT00972439 - Oral Contraceptive (OC) Progestin Dose and Breast Proliferation N/A
Completed NCT01076582 - Comparative Trial in Hormone Withdrawal Associated Symptoms Phase 3
Completed NCT00471991 - Valette (Combined Oral Contraceptive SH T04769G and SH D00659AF) Low Ovulation Inhibition Phase 2
Completed NCT00248963 - Study Evaluating Levonorgestrel and Ethinyl Estradiol in Oral Contraception Phase 3